-transparent.png){kind=logo}
P16INK4 is a cell cycle regulator that specifically binds to and inactivates cyclin-dependent kinase 4 (CDK4). Its encoding gene (p16/CDKN2) maps to chromosome 9p21, a region that undergoes frequent loss of heterozygosity in a variety of human tumors. We have analyzed the p16/CDKN2 gene and its expression in a series of primary glioma samples. Although homozygous deletion or mutation of the p16/CDKN2 gene was uncommon in this series and P16INK4 protein was detectable in all grade II tumors, it was present in only 50% of grade III and grade IV samples. Conversely, in some grade IV tumors that level of P16INK4 protein was elevated; in these cases, its target, CDK4, was amplified and overexpressed. These results suggest: (a) the involvement of P16INK4 in glioma progression; (b) that mechanisms other than mutation or deletion can down-regulate expression of the p16/CDKN2 gene; and (c) that the balance between CDK4 and its cognate inhibitor, P16INK4, may confer a cell growth advantage and facilitate tumor progression.
R Nishikawa, and
F B Furnari, and
H Lin, and
W Arap, and
M S Berger, and
W K Cavenee, and
H J Su Huang
July 2011,
The Journal of pathology,
R Nishikawa, and
F B Furnari, and
H Lin, and
W Arap, and
M S Berger, and
W K Cavenee, and
H J Su Huang
February 2020,
Cells,
R Nishikawa, and
F B Furnari, and
H Lin, and
W Arap, and
M S Berger, and
W K Cavenee, and
H J Su Huang
January 1997,
British journal of cancer,
R Nishikawa, and
F B Furnari, and
H Lin, and
W Arap, and
M S Berger, and
W K Cavenee, and
H J Su Huang
June 2000,
Journal of neurosurgery,
R Nishikawa, and
F B Furnari, and
H Lin, and
W Arap, and
M S Berger, and
W K Cavenee, and
H J Su Huang
November 2012,
Brain pathology (Zurich, Switzerland),
R Nishikawa, and
F B Furnari, and
H Lin, and
W Arap, and
M S Berger, and
W K Cavenee, and
H J Su Huang
December 1999,
British journal of cancer,
R Nishikawa, and
F B Furnari, and
H Lin, and
W Arap, and
M S Berger, and
W K Cavenee, and
H J Su Huang
September 2008,
Oncology reports,
R Nishikawa, and
F B Furnari, and
H Lin, and
W Arap, and
M S Berger, and
W K Cavenee, and
H J Su Huang
August 2014,
Oncogene,
R Nishikawa, and
F B Furnari, and
H Lin, and
W Arap, and
M S Berger, and
W K Cavenee, and
H J Su Huang
August 2011,
Current treatment options in neurology,
R Nishikawa, and
F B Furnari, and
H Lin, and
W Arap, and
M S Berger, and
W K Cavenee, and
H J Su Huang
December 2017,
Continuum (Minneapolis, Minn.),
